Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: Biogen
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• Conformed diagnosis of follicular lymphoma, grades 1,2 or 3

• No prior chemotherapy

• No prior monoclonal antibody therapy

• Bulky or symptomatic disease, stage II-IV

• Performance status 0-2

Exclusion Criteria:

• Impaired bone marrow reserve

• Presence of CNS lymphoma

• Serious nonmalignant disease or active infection